Karyopharm Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Karyopharm Therapeutics wird ein Gewinn- und Umsatzwachstum von 40.1% bzw. 23.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 48.6% pro Jahr wachsen soll.

Wichtige Informationen

35.2%

Wachstumsrate der Gewinne

48.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.6%
Wachstumsrate der Einnahmen	23.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	10 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Benign Growth For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Underpins Stock's 28% Plummet

Apr 27

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Feb 23

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Feb 05

Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Apr 17

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 17

Karyopharm: Market Is Overlooking Growth

Oct 07

Karyopharm Therapeutics Q2 2022 Earnings Preview

Aug 03

Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU

Jul 20

Karyopharm: Another 2 Year Wait For Data

May 05

Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates

Feb 19

Karyopharm Therapeutics: Unjustified Sell-Off Provides An Opportunity To Reload My Position

Dec 04

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:KPTI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	234	-114	N/A	N/A	5
12/31/2025	165	-146	N/A	N/A	6
12/31/2024	145	-149	N/A	N/A	6
3/31/2024	140	-146	-118	-118	N/A
12/31/2023	146	-143	-93	-93	N/A
9/30/2023	146	-140	-101	-101	N/A
6/30/2023	146	-142	-100	-100	N/A
3/31/2023	148	-158	-109	-109	N/A
12/31/2022	157	-165	-150	-150	N/A
9/30/2022	250	-88	-97	-97	N/A
6/30/2022	251	-104	-99	-93	N/A
3/31/2022	234	-108	-119	-113	N/A
12/31/2021	210	-124	-113	-107	N/A
9/30/2021	119	-206	-169	-163	N/A
6/30/2021	102	-208	-184	-184	N/A
3/31/2021	113	-201	-168	-168	N/A
12/31/2020	108	-196	-160	-160	N/A
9/30/2020	91	-201	-169	-169	N/A
6/30/2020	83	-189	-161	-161	N/A
3/31/2020	59	-186	-169	-169	N/A
12/31/2019	41	-200	-191	-191	N/A
9/30/2019	23	-209	-201	-200	N/A
6/30/2019	10	-216	-203	-202	N/A
3/31/2019	20	-206	-193	-191	N/A
12/31/2018	30	-178	-161	-159	N/A
9/30/2018	32	-159	-118	-116	N/A
6/30/2018	31	-142	-100	-100	N/A
3/31/2018	12	-138	-84	-84	N/A
12/31/2017	2	-129	N/A	-74	N/A
9/30/2017	0	-117	N/A	-88	N/A
6/30/2017	0	-112	N/A	-87	N/A
3/31/2017	0	-112	N/A	-86	N/A
12/31/2016	0	-110	N/A	-84	N/A
9/30/2016	0	-112	N/A	-85	N/A
6/30/2016	0	-117	N/A	-90	N/A
3/31/2016	0	-119	N/A	-97	N/A
12/31/2015	0	-118	N/A	-94	N/A
9/30/2015	0	-115	N/A	-86	N/A
6/30/2015	0	-104	N/A	-77	N/A
3/31/2015	0	-88	N/A	-61	N/A
12/31/2014	0	-76	N/A	-51	N/A
9/30/2014	0	-62	N/A	-49	N/A
6/30/2014	0	-52	N/A	-41	N/A
3/31/2014	0	-42	N/A	-36	N/A
12/31/2013	0	-34	N/A	-30	N/A
9/30/2013	0	-26	N/A	-24	N/A
6/30/2013	0	-20	N/A	-19	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KPTI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: KPTI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: KPTI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: KPTIDie Einnahmen des Unternehmens (23.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: KPTIDie Einnahmen des Unternehmens (23.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von KPTI in 3 Jahren voraussichtlich hoch sein wird

Karyopharm Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year of 2024

Consensus EPS estimates fall by 16%

Price target decreased by 7.7% to US$6.00

Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024

Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023

Price target decreased by 15% to US$5.50

Recent updates

Karyopharm Therapeutics Inc. announced that it expects to receive $100 million in funding

Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year of 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Karyopharm Therapeutics Inc. to Report Q1, 2024 Results on May 08, 2024

Benign Growth For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Underpins Stock's 28% Plummet

Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting

Karyopharm Therapeutics Inc., Annual General Meeting, May 29, 2024

New minor risk - Shareholder dilution

New minor risk - Insider selling

Consensus EPS estimates fall by 16%

Full year 2023 earnings: EPS misses analyst expectations

Price target decreased by 7.7% to US$6.00

Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Karyopharm Therapeutics Inc. to Report Q4, 2023 Results on Feb 29, 2024

New major risk - Share price stability

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023

Karyopharm Therapeutics Receives Non-Compliance Notice From Nasdaq

Karyopharm Therapeutics Inc. Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi-Naive Myelofib) Patients

Karyopharm Therapeutics Inc. Announces Resignation of Peter K Honig as Member of the Board of Directors

Price target decreased by 15% to US$5.50

Karyopharm Therapeutics Inc. Reiterates Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Karyopharm Therapeutics Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

Karyopharm Therapeutics Inc. Appoints Zhen Su to Its Board of Directors

Consensus EPS estimates upgraded to US$1.02 loss

Karyopharm Therapeutics Inc. Announces Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Karyopharm Therapeutics Inc. to Report Q2, 2023 Results on Aug 02, 2023

Karyopharm Therapeutics Inc. Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer

Karyopharm Therapeutics Inc. Initiates Pivotal Phase 3 Clinical Trial (XPORT-MF-034) to Assess Efficacy and Safety of Once-Weekly Selinexor 60Mg in Combination with Ruxolitinib in JAKi-Naïve Patients with Myelofibrosis

Consensus EPS estimates upgraded to US$1.28 loss, revenue downgraded

Price target decreased by 12% to US$7.60

Karyopharm Therapeutics Inc. Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

President recently sold US$100k worth of stock

Karyopharm Therapeutics Inc. Provides Revenue Guidance for the Full Year 2023

Full year 2022 earnings: EPS misses analyst expectations

Karyopharm Therapeutics Inc. to Report Q4, 2022 Results on Feb 15, 2023

Price target decreased to US$8.89

Karyopharm Therapeutics Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Karyopharm Therapeutics Inc. Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022

Karyopharm Therapeutics Inc. announced that it expects to receive $165.000003 million in funding from a group of investors

High number of new directors

Third quarter 2022 earnings released: US$0.45 loss per share (vs US$0.69 loss in 3Q 2021)

Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Fiscal Year 2022

Karyopharm Therapeutics Inc. and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Karyopharm Therapeutics Inc. to Report Q3, 2022 Results on Nov 03, 2022

Karyopharm: Market Is Overlooking Growth

Key Executive notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$10.44

Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2022

Karyopharm Therapeutics Q2 2022 Earnings Preview

Karyopharm Therapeutics Inc. to Report Q2, 2022 Results on Aug 04, 2022

Karyopharm Therapeutics Inc. and Menarini Group Receives Full Marketing Authorisation from the European Commission for NEXPOVIO

Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU

Karyopharm Therapeutics Inc. Receives Health Canada Authorization for XPOVIO® (selinexor)

The European Myeloma Network and Karyopharm Therapeutics Inc. Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study

Karyopharm Therapeutics Inc. and Menarini Group Receive Positive Chmp Opinion for Nexpovio® (Selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

President recently sold US$178k worth of stock

Karyopharm: Another 2 Year Wait For Data

Price target decreased to US$12.20

High number of new directors

Price target decreased to US$12.20